Merck Animal Health, Madison, New Jersey, has announced the Food and Drug Administration’s approval of an expanded indication for Banamine Transermal (flunixin transdermal solution).
The new indication is for the control of pyrexia (fever) due to acute mastitis with a short milk withhold of 48 hours.
In a multi-site field study, 95% of dairy cows with acute mastitis had a reduction in fever of 2 degrees Fahrenheit for more than six hours after treatment with Banamine Transdermal compared to 35% of untreated controls.
Introduced in 2018, the product is the first and only FDA-approved product for pain control in a food-producing animal, and the first and only non-steroidal, anti-inflammatory available as a pour-on.
It is a prescription product labeled for control of fever associated with bovine respiratory disease and acute mastitis, and for control of pain associated with foot rot.
For more information, see a veterinarian or visit BanamineTD.com.
